Quince Therapeutics, Inc. 8-K

What Happened

• Quince Therapeutics, Inc. (QNCX) filed an 8‑K reporting the results of its annual meeting held online via webcast on June 11, 2026. Approximately 6,255,339 shares were represented, about 38.37% of outstanding shares eligible to vote. Stockholders approved an amendment to the company’s certificate of incorporation to permit a reverse stock split at a ratio between 1‑for‑10 and 1‑for‑100, to be implemented at the board’s discretion.

Key Details

• Director election: June Bray was elected as a Class I director to serve until the 2029 annual meeting — Votes For: 2,430,964; Votes Withheld: 216,735; Broker Non‑Votes: 3,607,640.
• Reverse stock split authorization: Approved — Votes For: 4,715,574; Votes Against: 1,517,896; Abstentions: 21,866. Board may decide whether and when to effect the split and the exact ratio within the approved range.
• Auditor ratification: BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal 2026 — Votes For: 6,080,608; Votes Against: 111,522; Abstentions: 63,207.
• Say‑on‑pay (advisory): Approved — Votes For: 2,504,778; Votes Against: 116,876; Abstentions: 26,044; Broker Non‑Votes: ~3,607,641.
• Adjournment authority: Approved to permit further solicitation if needed — Votes For: 5,236,032; Votes Against: 987,376; Abstentions: 31,929.

Why It Matters

• The reverse stock split authorization gives the board the power to reduce the number of outstanding shares within a wide range (1‑for‑10 to 1‑for‑100); if implemented, the split will change the share count and per‑share metrics and may be used for strategic or listing‑related reasons.
• The director election and auditor ratification are routine governance outcomes; the advisory approval of executive compensation is non‑binding but indicates stockholder sentiment.
• Voter turnout was relatively low (~38.4%), and there were substantial broker non‑votes (~3.6M), which affected vote totals on certain proposals (notably the director election and say‑on‑pay).